Systematic Financial Management LP Increases Stake in Integra LifeSciences Holdings Corporation $IART

Key Points

• Systematic Financial Management LP increased its stake in Integra LifeSciences Holdings Corporation by 8.9%, acquiring an additional 76,271 shares, bringing its total ownership to approximately 1.21% of the company.
• Integra LifeSciences reported a Q2 earnings per share of $0.45, beating the consensus estimate of $0.43, and had revenue of $415.61 million, exceeding expectations of $395.06 million.
• JPMorgan Chase & Co. and Wells Fargo & Company both lowered their price targets on Integra LifeSciences significantly, reflecting cautious market sentiment around the stock.

Systematic Financial Management LP lifted its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 8.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 936,834 shares of the life sciences company's stock after buying an additional 76,271 shares during the quarter. Systematic Financial Management LP owned about 1.21% of Integra LifeSciences worth $20,601,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Arizona State Retirement System increased its position in shares of Integra LifeSciences by 4.2% during the first quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock worth $437,000 after buying an additional 795 shares during the period. Envestnet Asset Management Inc. increased its position in shares of Integra LifeSciences by 4.6% during the first quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company's stock worth $605,000 after buying an additional 1,204 shares during the period. Sei Investments Co. increased its position in shares of Integra LifeSciences by 7.4% during the first quarter. Sei Investments Co. now owns 20,351 shares of the life sciences company's stock worth $451,000 after buying an additional 1,398 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Integra LifeSciences by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after buying an additional 1,437 shares during the period. Finally, MetLife Investment Management LLC increased its position in shares of Integra LifeSciences by 5.3% during the fourth quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company's stock worth $947,000 after buying an additional 2,111 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. JMP Securities reduced their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Wells Fargo & Company reduced their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Integra LifeSciences currently has a consensus rating of "Reduce" and a consensus target price of $18.43.

Integra LifeSciences Stock Down 2.0%

Shares of IART traded down $0.30 during trading hours on Thursday, reaching $14.57. 502,092 shares of the stock traded hands, compared to its average volume of 1,040,698. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -2.23, a PEG ratio of 0.83 and a beta of 1.16. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. Integra LifeSciences Holdings Corporation has a 52 week low of $11.06 and a 52 week high of $27.13. The stock has a fifty day simple moving average of $12.92 and a 200 day simple moving average of $16.23.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The business had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same quarter in the previous year, the company earned $0.63 EPS. The business's quarterly revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.